Compare DexCom, Inc. (DXCM) vs Opendoor Technologies Inc (OPEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Opendoor Technologies Inc — how do they compare? DexCom, Inc. trades at $84.38 (market cap $31.81B), while Opendoor Technologies Inc trades at $2.31 (market cap $2.20B). The key difference: DexCom, Inc. is far larger — about 14.5× Opendoor Technologies Inc's market cap, and DexCom, Inc. is trading nearer its 52-week high, Opendoor Technologies Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Opendoor Technologies Inc for 33 Days on average.
| DXCM | OPEN | |
|---|---|---|
Market Cap | $31.81B | $2.20B |
Volume | 2,861,821 | 35,582,488 |
Sector | Health | Real Estate |
52-Week High | $92.34 | $9.37 |
52-Week Low | $54.84 | $2.27 |
Typical Hold Time | 62 Days | 33 Days |
Enterprise Value | $31.26B | $3.27B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $84.41, showing modest daily gains of 1.22% amid a bearish technical outlook. The company demonstrates strong fundamental performance with consistent earnings beats, including Q2 2026 EPS of $0.70 exceeding expectations of $0.611. Revenue growth remains robust, climbing from $2.9B in 2022 to $4.7B in 2025, while net income margins improved to 17.93%. Recent news highlights expansion opportunities in Type 2 diabetes care and executive promotions.
Wall Street maintains a bullish stance with 81% buy ratings and a $95.07 consensus price target, representing 13% upside potential. Key risks include competitive pressures in CGM markets and reimbursement challenges. The company's strong cash flow generation and expanding market opportunity in diabetes technology support long-term growth prospects despite current technical weakness.
Opendoor Technologies trades at $2.29, up 0.88% with a bearish technical outlook. The company shows concerning fundamentals with a -46.74% net income margin and -$1.3B net loss despite $4.37B revenue. Recent earnings misses and negative cash flow trends highlight operational challenges, though mortgage expansion to 35-40 states by end-2026 offers potential growth. Analyst consensus is mixed with 26.9% buy ratings but a $4.92 price target suggesting 115% upside from current levels.
The stock presents high-risk speculative potential with significant operational turnaround required. While valuation appears attractive at 0.62 P/S ratio, persistent losses and housing market sensitivity create substantial downside risk. The mortgage expansion initiative could drive recovery if execution improves, but investors face volatility from rate sensitivity and competitive pressures in the iBuyer space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Opendoor Technologies Inc
Opendoor Technologies Inc is a digital platform for residential real estate. This platform enables customers to buy and sell houses online. It generates revenue through home sales, along with other revenue from real estate services.
Read more on OPEN →
